HD-IMMUNE-GMBH
24.1.2024 04:41:35 CET | Business Wire | Press release
HD Immune GmbH (HDI), a privately held biotechnology company developing novel antibody treatments for Huntington’s Disease, announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman. HDI has acquired the patents and assets of the Huntington’s disease program from AFFiRiS AG. HDI has also closed a pre-seed financing round with an Austrian Business Angel and awarded an Austria Wirtschafts Service (AWS) pre-seed Grant. Furthermore, HDI announces the successful application with the Austrian Centre of Industrial Biotechnology (acib) Comet24 program allowing for HDI to collaborate with the Institute of Molecular Biotechnology (BOKU, University of Natural Resources and Life Sciences, Vienna) for HDI’s research programs.
Dr. Stefan Bartl, CEO of HDI, comments: “With the acquirement of the Huntington’s disease program that I was developing previously at AFFiRiS AG, HD Immune starts in a position where we have very impressive pre-clinical data demonstrating the efficacy of treating transgenic model of Huntington’s Disease with our lead monoclonal antibody C6-17, which has been recently published. We are in the process of humanizing this antibody for the treatment of patients aiming to slow down the progression of the disease, thereby increasing the quality of life for the patient. Currently there are no therapies that can directly treat the mutant Huntingtin protein available for patients.”
HD Immune’s new pre-clinical publication can be found on the company webpage for downloading: www.hdimmune.com
HD Immune and Huntington’s Disease
Huntington’s disease (HD) is a fatal neurodegenerative disease with clinical symptoms becoming manifest typically in the fourth decade of life and progress to a severe neurological and psychiatric deterioration of the patient. HD is a rare monogenetic disorder, where the mutation leads to a structurally changed mutant Huntingtin protein (mtHTT) which forms aggregates in the brain.
HD Immune is developing an antibody to target the mutated protein and remove it from the body. HDI has a lead antibody mAB C6-17 which lowers mtHTT in the blood, organs and CNS and, further, improved motor performance in transgenic mice expressing human mutant protein. Based on these results, HD Immune intends to further advance the development of a human therapeutic antibody to reduce the symptoms of the disease in the patient.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122135838/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage and C3 AI Partner on Network-Enabled, Agentic AI Field Services Solution for Mobile Workforces11.2.2026 09:30:00 CET | Press release
Designed for mission-critical field operations, the joint solution combines autonomous and assisted AI with Vonage communications and network APIs for those working beyond the enterprise edge Vonage, part of Ericsson (NASDAQ: ERIC), today announced a strategic collaboration with C3 AI (NYSE: AI), a leading Enterprise AI application software provider, to launch C3 AI Field Services, a module of the C3 AI Asset Performance Suite of products, integrated with Vonage APIs. The AI-first module combines C3 AI’s powerful Enterprise AI capabilities with Vonage’s cutting-edge Communications APIs (Voice and Video) and Network APIs (Quality on Demand and Verify), to deliver superior performance, reliability and experiences for mobile enterprise field operations. This collaboration builds on a broader network-powered solutions offering from Vonage where application-aware networking, including advanced connectivity capabilities such as Quality on Demand (QoD), can be applied to support critical fiel
Mobileum and NOHOLD Launch White-Labeled AI Assistant Offering for Telecom Enterprise Customers11.2.2026 09:00:00 CET | Press release
First product release following the companies’ strategic AI alliance enables operators to monetize AI services for SME/SMBs through existing telco channels Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and NOHOLD, a leader in enterprise-grade AI assistant platforms, have announced the launch of a new white-labeled AI Assistant solution designed specifically for telecom operators serving small and medium-sized enterprises (SME/SMBs). The new offering builds on the strategic AI alliance announced in September 2025, moving from concept to a market-ready solution. Telecom operators can now offer branded AI Assistant services that help SME/SMBs enhance customer engagement, drive sales, and improve productivity through AI technology, with operators providing the tools so SME/SMBs avoid managing complex AI themselves. As traditional connectivity revenues continue to be under pressure, SME/SMBs are seeking value-added digital services from their tele
Merus Power leverer et energilagringssystem til ekstreme arktiske forhold11.2.2026 08:00:00 CET | Pressemeddelelse
Merus Power Oyj har indgået en aftale om levering af et batterienergilagringssystem til en værdi af cirka 13 mio. euro med Neve Oy. Anlægget på 30 MW/80 MWh er designet til at fungere under ekstremt kolde forhold og vil blive leveret til Rovaniemi ved udgangen af 2026. Virksomhederne har desuden indgået aftale om omfattende drifts- og vedligeholdelsestjenester for energilagringsanlægget. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260205135896/da/ Merus Power delivered the first grid forming battery energy storage systems in the Nordics last year. The grid forming BESS to be deployed in Lapland is also designed to withstand extreme Arctic conditions. Energilagringsanlægget er konstrueret til at fungere pålideligt under arktiske forhold og kan modstå temperaturer helt ned til -50 °C samt kraftigt snefald og is. Systemet anvender grid forming-teknologi, som understøtter elnettets inerti og styrker stabiliteten i el-system
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™11.2.2026 07:00:00 CET | Press release
Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2 Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprieta
Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom